Northern Trust Corp increased its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 9.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 750,442 shares of the biopharmaceutical company’s stock after purchasing an additional 66,677 shares during the period. Northern Trust Corp owned approximately 1.20% of Dynavax Technologies worth $11,445,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of DVAX. Wells Fargo & Company MN lifted its position in Dynavax Technologies by 9.2% during the 1st quarter. Wells Fargo & Company MN now owns 45,516 shares of the biopharmaceutical company’s stock worth $903,000 after acquiring an additional 3,834 shares during the last quarter. Creative Planning lifted its position in Dynavax Technologies by 2.6% during the 2nd quarter. Creative Planning now owns 235,105 shares of the biopharmaceutical company’s stock worth $3,585,000 after acquiring an additional 5,857 shares during the last quarter. Guggenheim Capital LLC lifted its position in Dynavax Technologies by 7.2% during the 1st quarter. Guggenheim Capital LLC now owns 112,278 shares of the biopharmaceutical company’s stock worth $2,228,000 after acquiring an additional 7,522 shares during the last quarter. Alps Advisors Inc. lifted its position in Dynavax Technologies by 11.2% during the 2nd quarter. Alps Advisors Inc. now owns 90,375 shares of the biopharmaceutical company’s stock worth $1,378,000 after acquiring an additional 9,103 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new position in Dynavax Technologies during the 1st quarter worth $199,000. Hedge funds and other institutional investors own 81.48% of the company’s stock.
DVAX has been the subject of a number of research analyst reports. ValuEngine lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Monday, July 30th. Royal Bank of Canada boosted their target price on shares of Dynavax Technologies to $26.00 and gave the stock an “outperform” rating in a research report on Monday, October 22nd. Zacks Investment Research raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, July 24th. BidaskClub lowered shares of Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 18th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a research report on Monday, October 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $28.00.
Dynavax Technologies stock opened at $12.09 on Friday. The firm has a market cap of $756.69 million, a price-to-earnings ratio of -6.99 and a beta of 0.61. The company has a debt-to-equity ratio of 0.76, a current ratio of 8.87 and a quick ratio of 8.67. Dynavax Technologies Co. has a fifty-two week low of $9.63 and a fifty-two week high of $22.80.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.08). The company had revenue of $1.46 million for the quarter, compared to analyst estimates of $3.16 million. Dynavax Technologies had a negative net margin of 5,044.85% and a negative return on equity of 87.67%. The firm’s quarterly revenue was up 2822.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.38) EPS. Equities analysts forecast that Dynavax Technologies Co. will post -2.49 earnings per share for the current fiscal year.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Featured Article: How to Invest in a Bull Market
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.